English | Español

Genentech Inc.
Press release submission | Sep 16, 2018

GENENTECH INC: FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA), a Rare Form of Juvenile Arthritis

Trending
+ Technology/Innovation
Patient Daily News Service | Oct 9, 2025

Babylon Health collapse raises questions about AI claims across industries
Patient Daily | Oct 9, 2025

Medfluence Advisors Marketing Expert: 'The conversations leading into AAO-HNSF are shaping how ENT practices approach growth and engagement'
+ Pharmaceuticals
Patient Daily | Oct 8, 2025

American Lung Association launches campaign urging vaccinations against seasonal flu and respiratory illnesses
Patient Daily | Oct 6, 2025

Drug Channels Institute president: ‘A growing share of 340B dollars are captured by for-profit pharmacies and PBMs’